Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for Grade I/II Acute GVHD
NCT01596075Phase 2Unknown
- Sponsor
- Rabin Medical Center
- Start
- Jul 2012
- Primary completion
- Jul 2015
- Countries
- 1
01
Overview
Phase 2, open-label trial of cannabidiol in graft-versus-host disease (GVHD), sponsored by Rabin Medical Center. Primary endpoint: Complete resolution of acute graft versus host disease at 90 days. Status: unknown.
02
Drugs
cannabidiol
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01596075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01596075.